 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- || basroparib (STP1002) - Dong / A
Trial completion, Trial completion date, Trial primary completion date, Metastases: First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors (clinicaltrials.gov) - Feb 2, 2024
P1, N=32, Completed, Sponsor: ST Pharm Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Mar 2023 | Trial primary completion date: Sep 2023 --> Mar 2023
- || basroparib (STP1002) - Dong / A
Enrollment closed, Trial primary completion date, Metastases: First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors (clinicaltrials.gov) - Aug 1, 2023
P1, N=32, Active, not recruiting, Sponsor: ST Pharm Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Mar 2023 | Trial primary completion date: Sep 2023 --> Mar 2023 Recruiting --> Active, not recruiting | Trial primary completion date: May 2023 --> Sep 2023
- STP1002 - Dong / A
Tankyrase-selective inhibitor STP1002 reverses resistance to MEK inhibitors in colorectal cancer with KRAS mutations (Section 17; Poster Board #22) - Mar 14, 2023 - Abstract #AACR2023AACR_2551;
Dual combination of STP1002 and MEK inhibitor is a promising candidate to overcome resistance to MEK inhibitors in colorectal cancer with KRAS-G12V/G12D mutations. The phase 1 clinical trial study is ongoing in order to show safety margin.
- | basroparib (STP1002) - Dong / A
Trial completion date, Trial primary completion date, Metastases: First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors (clinicaltrials.gov) - Dec 28, 2022
P1, N=30, Recruiting, Sponsor: ST Pharm Co., Ltd.
The phase 1 clinical trial study is ongoing in order to show safety margin. Trial completion date: Mar 2022 --> Sep 2023 | Trial primary completion date: Dec 2021 --> May 2023
- | STP1002 - Dong / A
Preclinical, Journal, PARP Biomarker: Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract. (Pubmed Central) - Sep 2, 2022
These results demonstrate that STP1002, a novel, orally active tankyrase inhibitor, shows preclinical antitumour efficacy without on-target toxicity in the GI tract. Our data provide a rationale for a clinical trial on STP1002 as a potential tankyrase-targeted drug in patients with APC-mutated CRC.
- | basroparib (STP1002) - Dong / A
Trial completion date, Trial primary completion date, Metastases: First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors (clinicaltrials.gov) - Sep 28, 2021
P1, N=30, Recruiting, Sponsor: ST Pharm Co., Ltd.
Our data provide a rationale for a clinical trial on STP1002 as a potential tankyrase-targeted drug in patients with APC-mutated CRC. Trial completion date: Jul 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Dec 2021
- || basroparib (STP1002) - Dong / A
New P1 trial, Metastases: First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors (clinicaltrials.gov) - Aug 9, 2020
P1, N=30, Recruiting, Sponsor: ST Pharm Co., Ltd.